Overview of Long-term Follow-up from MonumenTAL-1
Focusing on the MonumenTAL-1 study, Mary Steinbach, APRN, provides clinical insights on nail, skin, and oral toxicities associated with talquetamab.
GPRC5D Therapy: Unique Challenges in Adverse Event Management
Lisa Hwa, APRN, DNP, CNP, FAPO, describes the unique challenges in managing adverse events associated with GPRC5D therapy compared with other bispecifics.
Adverse Event Management with BCMA Therapy
Ellen Marin, PA-C, provides an overview of adverse effects associated with BCMA-directed bispecific therapy in multiple myeloma.
Long-Term Follow-up Overview: MajesTEC-1 and MagnetisMM-3 Recent Data
A panel of experts on multiple myeloma discuss long-term follow-up data from the MajesTEC-1 and MagnetisMM-3 clinical trials.